{"ticker": {"uuid": "a084e0fb-85e6-4292-928e-6de3377fa486", "symbol": "2256", "name": "Abbisko Cayman Limited", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Allianz SE has acquired an additional 599,000 ordinary shares of Abbisko Therapeutics Co., Ltd. (HKEX: 2256), valued at approximately HK$6.8354 million.", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOeWExOEpLSmhkd0x4bGtiMTYycFBseGNCbFo5ZlNEYWpueklMcjhza21HRzJ5OEhualhtbjFCX3Y3VXBxS3dhcFhnSWJpSTJrTUQ4Sm5ReGJld0wxS3A4NVEzMGRfYjhfZGZpd0V6eERrVHZXY1hTeTRqZ1FjNkw5NmtGNmJCWmhveVI0ZDBjci10ZkViUFNqSkhnOWQ1b3ZPSEFWazY0dw?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-10T22:33:42+00:00", "published_display": "10 Jul 2026 22:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNWGpRUVJraGx5RC0wMDBEOWptYnZWQ1BOQkNHVzhfUE9oVkZ4dW9BZDc3QS1uS1N1MF9uZFNud2cyZFdTNG5DR2FVVVhFSXhUSThvWlpoZHd3T2dHcEZrdzBLRUV5dk00bk9VbUVaQm9xSDFzZl9PZ2RJV1RRdGZRcjNJTURldmtraktNWWk2U01jSFdjUjVDNV9XRmYtbjI3SmJLQkQ5amF4ZmVnaUpYcWZOVm1uNEhkb2duQ3VFRmx1OGpLODlHTDNzbThiaWdWMnpHelduNENMSjA?oc=5", "source_name": "Reuters", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbisko Therapeutics enters potential US$1.9 billion R&D deal with Eli Lilly", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQTTZYNklGbDZuNTFfZ2tqendRSFFFY3lkLVZSYllfX0NITFVxdnltaktJOUYyVEU5OFRhcURkN3RISXJOTnBlUGluNWNQUndZUzN3b1JvXzZ2LVFndjN4blhjSEVvUlpTaV9DSzNwbWhKVndobEhyMVh5eGFJWVJWNEVTVm1sTmZ3SkhmVU5YRUJ1Qm9WUjVXRV9UTFNIS1cxdU5HNGZQaGxzTDlkeU01d2Y0U2F3aWFPZnhSVGFpWUxENEhpdGc?oc=5", "source_name": "The Standard (HK)", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbisko Deepens Lilly Partnership in Multitarget Drug R&D Deal Worth Up to US$1.9 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPOFJzUXdwOTlGNW16YS1OX0FIMFJnbDJVT0dfX09TR0NHX1JTc1RXMUJoekhjcTNEbzJmcWRhdUdTT21VNzhqc2p0TXM1SWJ0TEViVmNHM3h0RXR4Vy1KbVU4Y0JpYUVNQW1NNGJrbnJMRWRwMVBGUF9wcm1EWnJUd09wRjFyR1hBc1hFcGYzMVAtbEtPWnh0SWczT2JiN3VrWkFjVk94Nkl4WU9vaUI0QTR2YTNSUFVTRkhhdzdpOFlHX3Z0a1VBX0dRcVE3ejE4RDVBVHpB?oc=5", "source_name": "TipRanks", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Allianz SE has acquired an additional 599,000 ordinary shares of Abbisko Therapeutics Co., Ltd. (HKEX: 2256), valued at approximately HK$6.8354 million.", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOeWExOEpLSmhkd0x4bGtiMTYycFBseGNCbFo5ZlNEYWpueklMcjhza21HRzJ5OEhualhtbjFCX3Y3VXBxS3dhcFhnSWJpSTJrTUQ4Sm5ReGJld0wxS3A4NVEzMGRfYjhfZGZpd0V6eERrVHZXY1hTeTRqZ1FjNkw5NmtGNmJCWmhveVI0ZDBjci10ZkViUFNqSkhnOWQ1b3ZPSEFWazY0dw?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-10T22:33:42+00:00", "published_display": "10 Jul 2026 22:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNWGpRUVJraGx5RC0wMDBEOWptYnZWQ1BOQkNHVzhfUE9oVkZ4dW9BZDc3QS1uS1N1MF9uZFNud2cyZFdTNG5DR2FVVVhFSXhUSThvWlpoZHd3T2dHcEZrdzBLRUV5dk00bk9VbUVaQm9xSDFzZl9PZ2RJV1RRdGZRcjNJTURldmtraktNWWk2U01jSFdjUjVDNV9XRmYtbjI3SmJLQkQ5amF4ZmVnaUpYcWZOVm1uNEhkb2duQ3VFRmx1OGpLODlHTDNzbThiaWdWMnpHelduNENMSjA?oc=5", "source_name": "Reuters", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbisko Therapeutics enters potential US$1.9 billion R&D deal with Eli Lilly", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQTTZYNklGbDZuNTFfZ2tqendRSFFFY3lkLVZSYllfX0NITFVxdnltaktJOUYyVEU5OFRhcURkN3RISXJOTnBlUGluNWNQUndZUzN3b1JvXzZ2LVFndjN4blhjSEVvUlpTaV9DSzNwbWhKVndobEhyMVh5eGFJWVJWNEVTVm1sTmZ3SkhmVU5YRUJ1Qm9WUjVXRV9UTFNIS1cxdU5HNGZQaGxzTDlkeU01d2Y0U2F3aWFPZnhSVGFpWUxENEhpdGc?oc=5", "source_name": "The Standard (HK)", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbisko Deepens Lilly Partnership in Multitarget Drug R&D Deal Worth Up to US$1.9 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPOFJzUXdwOTlGNW16YS1OX0FIMFJnbDJVT0dfX09TR0NHX1JTc1RXMUJoekhjcTNEbzJmcWRhdUdTT21VNzhqc2p0TXM1SWJ0TEViVmNHM3h0RXR4Vy1KbVU4Y0JpYUVNQW1NNGJrbnJMRWRwMVBGUF9wcm1EWnJUd09wRjFyR1hBc1hFcGYzMVAtbEtPWnh0SWczT2JiN3VrWkFjVk94Nkl4WU9vaUI0QTR2YTNSUFVTRkhhdzdpOFlHX3Z0a1VBX0dRcVE3ejE4RDVBVHpB?oc=5", "source_name": "TipRanks", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 74, "total_relevant": 4, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 4, "score": 50, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 72, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 2.0, "count": 3}, {"event": "general", "label": "Market update", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 10.1, "latest_week": "2026-07-17", "one_week_move": -7.9, "four_week_move": 11.8, "twelve_week_move": -25.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.417199, "market_dynamics_buy_signal": false, "relative_strength": -20.398859, "fair_value_gap": 36.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.8393, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.9% over one week, +11.8% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "\u5bcc\u9014\u725b\u725b", "count": 1}, {"label": "Reuters", "count": 1}, {"label": "The Standard (HK)", "count": 1}, {"label": "TipRanks", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 3}, {"label": "Market update", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.9% over one week, +11.8% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Allianz SE has acquired an additional 599,000 ordinary shares of Abbisko Therapeutics Co., Ltd. (HKEX: 2256), valued at approximately HK$6.8354 million."}], "updated_at": "2026-07-18T14:57:03.231634+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}